Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
Cabazitaxel
EFC6193
NCT00417079
Prostatic Neoplasm, Prostate Cancer
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
August 2017

Powered by ideaPoint, Inc.